| Description | HBG1 Human Pre-designed siRNA Set A contains three designed siRNAs for HBG1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components HBG1 siRNA-1: 5 nmol (HPLC) HBG1 siRNA-2: 5 nmol (HPLC) HBG1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 HBG1 Human Pre-designed siRNA Set A contains three designed siRNAs for HBG1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components HBG1 siRNA-1: 5 nmol (HPLC) HBG1 siRNA-2: 5 nmol (HPLC) HBG1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | The Leuconostoc GPDH exhibits dual coenzyme specificity, namely NAD and NADP (Olive and Levy, Biochem., 6, 730 730, 1967). When assayed under conditions that are optimal for the particular coenzyme, the ratio of observed catalytic activity is NAD/NADP = 1.8 | Gly-Pro-pNA hydrochloride is a dipeptidyl peptidase inhibitor that inhibits dipeptidyl peptidase II, dipeptidyl peptidase IV and dipeptidyl peptidase IX | Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis... Read More | Inquire |